Why J&J Is Buying Actelion for $30 Billion
Interactive Video
•
Business
•
University
•
Hard
Wayground Content
FREE Resource
The video discusses the discrepancy between Octillion's offer price and current share price, highlighting the impact of Trump's policies on overseas cash use. It explores Johnson & Johnson's strategic acquisition to address revenue shortfalls due to Remicade's vulnerability to biosimilar competition. The discussion also covers the high valuation of the deal amidst potential drug price negotiations and market dynamics.
Read more
2 questions
Show all answers
1.
OPEN ENDED QUESTION
3 mins • 1 pt
In what way does the potential competition from biosimilars affect Johnson and Johnson's strategy?
Evaluate responses using AI:
OFF
2.
OPEN ENDED QUESTION
3 mins • 1 pt
What does the text suggest about the valuation of the deal in light of possible drug price negotiations?
Evaluate responses using AI:
OFF
Access all questions and much more by creating a free account
Create resources
Host any resource
Get auto-graded reports
Continue with Google
Continue with Email
Continue with Classlink
Continue with Clever
or continue with
Microsoft
%20(1).png)
Apple
Others
Already have an account?
